EZH2 and neoplasm: We found 3 crucial HLM regulators (EZH2, NSD2, and KMT5C) that were consistently highly expressed in advanced PCa stages and associated with various clinicopathological characteristics (tumor, GS > 7, pT3, HR > 1, and TP53 mutation).